View More Recent Stories

Oct 31, 2019 04:01PM Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
Oct 24, 2019 04:51PM Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1
Oct 24, 2019 04:01PM Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
Oct 10, 2019 04:03PM Aclaris Therapeutics (ACRS) Announces Divestiture of RHOFADE
Oct 10, 2019 04:02PM Aclaris Therapeutics Announces Divestiture of RHOFADE®
Oct 8, 2019 05:03PM Aclaris Therapeutics (ACRS) Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing ANDA for Generic Version of RHOFADE cream, 1%
Oct 8, 2019 05:01PM Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
Sep 17, 2019 07:00AM Aclaris Therapeutics to Hold R&D Day
Sep 16, 2019 04:17PM Aclaris Therapeutics (ACRS) Reports Positive Results from Phase 3 Clinical Trial, THWART-2 (WART-302), of A-101 45% Topical Solution
Sep 16, 2019 04:15PM Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
Sep 5, 2019 08:33AM Aclaris Therapeutics (ACRS) announces new strategic direction, will refocus on its immuno-inflammatory development programs
Sep 5, 2019 08:30AM Aclaris Therapeutics Announces New Strategic Direction
Aug 8, 2019 04:01PM Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
Jul 30, 2019 04:39PM Aclaris Therapeutics (ACRS) Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
Jul 30, 2019 04:01PM Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
Jul 9, 2019 07:03AM Aclaris Therapeutics (ACRS) Reports Issuance of Additional Orange Book Listable Patent Covering RHOFADE (Oxymetazoline Hydrochloride) Cream, 1%
Jul 9, 2019 07:00AM Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
Jul 5, 2019 05:44AM Aclaris Therapeutics (ACRS) Names Maxine Gowen to Board
Jul 3, 2019 04:01PM Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
Jun 26, 2019 04:02PM Aclaris Therapeutics (ACRS) Reports Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
Jun 26, 2019 04:01PM Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
Jun 17, 2019 06:07AM Aclaris Therapeutics (ACRS) Highlights Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical
Jun 17, 2019 06:00AM Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
Jun 14, 2019 04:01PM Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
May 24, 2019 07:00AM Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
May 8, 2019 04:01PM Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
May 1, 2019 07:00AM Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
Apr 25, 2019 07:00AM Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
Apr 24, 2019 07:14AM Aclaris Therapeutics (ACRS) Granted Patent Covering use of Ruxolitinib and Deuterated Forms to Treat Alopecia Areata
Apr 24, 2019 07:00AM Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
Mar 27, 2019 07:00AM Aclaris Therapeutics to Attend Upcoming Investor Conference
Mar 18, 2019 07:00AM Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
Jul 25, 2016 10:00AM Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories